Investment Thesis
Kymera is a pre-commercial biotech with a strong balance sheet but severe cash burn of $88.8M annually against only $144.1M cash, yielding approximately 1.6 years of runway. Declining revenue (-16.7% YoY) despite early-stage status signals pipeline commercialization challenges. Shareholder dilution is highly likely without significant capital injection or rapid clinical progress.
Strengths
- Zero debt with debt/equity of 0.00x and only $129.4M liabilities against $1.7B assets
- Exceptional liquidity with current ratio of 10.81x providing operational flexibility
- Substantial stockholders' equity of $1.5B offers financial cushion for development activities
Risks
- Cash runway of only 1.6 years at current $88.8M annual operating burn rate
- Revenue declining 16.7% YoY is a red flag for development-stage biotech with pipeline assets
- Operating margin of -244.9% indicates pipeline commercialization is not offsetting R&D spending
- Will require dilutive equity financing or debt within 18 months
- Biotech drug development execution risk with no guarantee of clinical or commercial success
Key Metrics to Watch
- Monthly operating cash burn rate and updated cash runway estimates
- Quarterly revenue trend and clinical trial milestones for pipeline assets
- Equity financing announcements and shareholder dilution impact
Financial Metrics
Revenue
34.4M
Net Income
-69.2M
EPS (Diluted)
$-0.71
Free Cash Flow
-89.3M
Total Assets
1.7B
Cash
144.1M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-244.9%
Net Margin
-201.5%
ROE
-4.5%
ROA
-4.1%
FCF Margin
-259.8%
Balance Sheet & Liquidity
Current Ratio
10.81x
Quick Ratio
10.81x
Debt/Equity
0.00x
Debt/Assets
7.8%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-06T18:06:01.241088 |
Data as of: 2026-03-31 |
Powered by Claude AI